Menu
This medication is currently available, Florida patients initial evaluation must be done in office, patients in New Jersey may utilize our Telemedicine program. Refills may be done online or by phone.
12.5mg Semaglutide Weight Loss Kit + B12 – Semaglutide acts like human glucagon-like peptide-1 (GLP-1) in that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, so a once-a-week injection is sufficient. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults. Our average weight loss for this 12 week program is 8-12% BMI reduction. This medication is FDA approved. It is not approved for patients with Type I Diabetes.
$789.00
This program may include compounded medications that are clinical substitutions of brand name medications compounded by licensed compounding pharmacies under section 503A/B. To learn more about the benefits, risks, & differences of compounded medication substitutes you may visit the FDA Drug Shortage List & FDA Compounding Substitutions Information Page. MedClub only utilizes pharmacies in the United States that adhere to the standards of practices under 503A, 503B, & 503C active licensing and acts in good faith that these standards will be upheld by each licensed compounding pharmacy. These compounds may have deviations from the brand name substitute. If you have questions about compounded medications, the approval process, testing requirements or licensing patients must contact their dispensing 3rd party pharmacy directly.
12.5mg Semaglutide Weight Loss Kit – Semaglutide acts like human glucagon-like peptide-1 (GLP-1) in that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, so a once-a-week injection is sufficient. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults. Semaglutide is the first of a new generation of highly effective hormone-based obesity medications. Semaglutide mimics a hormone called glucagon-like peptide-1 (GLP-1), which is secreted in the gut and targets receptors throughout the body, including the brain. When a person is eating, GLP-1 sends the brain the “I’m full” signal. The main way semaglutide helps treat obesity is through its action in the brain. For many people, the medication appears to work. The results of a clinical trial, published in The New England Journal of Medicine, showed in addition to the 12.5% mean weight reduction above the placebo group (which included lifestyle changes only) -more than a third of the participants (some of whom weighed more than 200 pounds) lost 20% of their weight. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) in that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, so a once-a-week injection is sufficient. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults. This compounded medication is not suitable for all patients, MedClub makes no claims as to the effectiveness of each individual program utilizing any compounded medication. We cannot guarantee any specific results, but have anecdotally witnessed an above average effectiveness when utilizing this medication to improve blood glucose, decrease appetite, and lower BMI over a sustained period of time.
Typical dosage structure:
DISCLAIMER – Each patients titration schedule is adjustable based on tolerance to each previous dose.
Read Our Weight Loss Article about semaglutide weight loss kits
Read our Physicians Guide to Weight Loss Drugs
Credit – New England Journal of Medicine, Yale Medicine
